Amgen Inc. (AMGN) Is Sinking Despite Study Results

Shutterstock photo

( - Amgen Inc. ( AMGN ) announced Friday morning that the 27,564-patient Repatha or evolocumab cardiovascular outcomes study, FOURIER, established for the first time that maximally reducing low-density lipoprotein cholesterol (LDL-C) levels with Repatha, beyond what is possible with the current best therapy alone, leads to a further reduction in major cardiovascular events, including heart attacks, strokes and coronary revascularizations.

Amgen has gapped open sharply lower this morning and is now down 10.96 at $168.15 on above average volume. The stock has tumbled to a 1-month low.

For comments and feedback: contact

This article appears in: Politics , Stocks , Stocks
Referenced Symbols: AMGN

More from RTT News


See headlines for AMGN

Follow on: